1 Magnetically Responsive Biomaterials for Non-Invasive Drug Delivery and Enhanced Wound Repair https://www.jourcc.com/index.php/jourcc/article/view/363 10.66224jcc.8.1.3 1 Multiple sclerosis (MS) is a chronic disease of the central nervous system (CNS) where immune mediated processes lead to demyelination and neurodegeneration, followed by the progressive loss of axonal functions. Current immunotherapy approaches suffer from various shortcomings, including low brain penetration, undesired systemic immunosuppression, and lack of repair promoting activity, while routine magnetic resonance imaging (MRI) requires the use of gadolinium based contrast agents with emerging evidence of their adverse effects on the CNS. During the last decade, the concept of theranostics has been actively developed and realized via the design of nanocomposite materials that possess both diagnostic and therapeutic functions. The current mini review highlights recent advances in various theranostic nano platforms for the treatment of MS. It includes SPION based systems allowing MRI visualization of focal inflammation and targeted drug delivery, polymeric nanoparticles for antigen specific immunomodulation, and carbohydrate based nanomaterials for their ability to harness intrinsic immunomodulatory properties. Recent studies showed the potential of these approaches to specifically deliver therapeutic cargo to the lesion site, enhance the visibility of plaques on MRI, and modulate the local immune response. Being used in combination with advanced hybrid imaging modalities such as MRI/PET, MRI/CT, or MRI/optical imaging, and augmented by AI powered image analysis, theranostic nanoparticles may enable real time visualization of the nanoparticle biodistribution and provide important mechanistic insights for each stage of the treatment. Altogether, theranostic nanocomposites represent a promising concept for the treatment of MS that may allow personalized and more efficient disease management. 1 10 AmirAbbas Amini School of Advanced Technologies in Medicine, Medical Image and Signal Processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran. Student Research Committee, Department of Neuroimaging, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran. Iran Amini.ieee@gmail.com Vahid Sadeghi School of Advanced Technologies in Medicine, Medical Image and Signal Processing Research Center, Isfahan University of Medical Sciences, Isfahan, Iran Poostchi Ophthalmology Research Center, Department of Ophthalmology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran Iran vahidsadeghi64119@gmail.com Meysam Mansouri Department of Research and Development, Avid Tejarat Apadana, Esfahan, Iran. Department of Electronic Engineering, University of Rome Tor Vergata, Rome, Italy. Iran mansouri.meysam@gmail.com Multiple sclerosis Theranostics SPIONs Targeted immunomodulation Multimodal imaging JCC8.8.1.3.pdf [1] A.J. Thompson, B.L. Banwell, F. Barkhof, W.M. Carroll, T. Coetzee, G. Comi, J. Correale, F. Fazekas, M. Filippi, M.S. Freedman, Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria, The Lancet Neurology 17(2) (2018) 162-173. ##[2] C. Walton, R. King, L. Rechtman, W. Kaye, E. Leray, R.A. Marrie, N. Robertson, N. La Rocca, B. Uitdehaag, I. van Der Mei, Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, Multiple Sclerosis Journal 26(14) (2020) 1816-1821. ##[3] C.A. Dendrou, L. Fugger, M.A. Friese, Immunopathology of multiple sclerosis, Nature Reviews Immunology 15(9) (2015) 545-558. ##[4] H. Lassmann, Multiple sclerosis pathology, Cold Spring Harbor perspectives in medicine 8(3) (2018) a028936. ##[5] X. Montalban, R. Gold, A.J. Thompson, S. Otero-Romero, M.P. Amato, D. Chandraratna, M. Clanet, G. Comi, T. Derfuss, F. Fazekas, ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis, Multiple Sclerosis Journal 24(2) (2018) 96-120. ##[6] S.L. Hauser, B.A. Cree, Treatment of multiple sclerosis: a review, The American journal of medicine 133(12) (2020) 1380-1390. e2. ##[7] G. Luna, P. Alping, J. Burman, K. Fink, A. Fogdell-Hahn, M. Gunnarsson, J. Hillert, A. Langer-Gould, J. Lycke, P. Nilsson, Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies, JAMA neurology 77(2) (2020). ##[8] F. Gosselet, R.A. Loiola, A. Roig, A. Rosell, M. Culot, Central nervous system delivery of molecules across the blood-brain barrier, Neurochemistry international 144 (2021) 104952. ##[9] D.M. Teleanu, C. Chircov, A.M. Grumezescu, A. Volceanov, R.I. Teleanu, Blood-brain delivery methods using nanotechnology, Pharmaceutics 10(4) (2018) 269. ##[10] T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, D. Takenaka, High signal intensity in the dentate nucleus and globus pallidus on unenhanced T1-weighted MR images: relationship with increasing cumulative dose of a gadolinium-based contrast material, Radiology 270(3) (2014) 834-841. ##[11] A. Amini, A. Shayganfar, Z. Amini, L. Ostovar, S. HajiAhmadi, N. Chitsaz, M. Rabbani, R. Kafieh, Deep learning for discrimination of active and inactive lesions in multiple sclerosis using non-contrast FLAIR MRI: A multicenter study, Multiple Sclerosis and Related Disorders 87 (2024) 105642. ##[12] A. Amini, A. Shayeganfar, Z. Amini, L. Ostovar, S. Hajiahmadi, N. Chitsaz, M. Rabbani, R. Kafieh, STRIKE-MS: Synergistic Texture and Raw Intensity Knowledge Extraction for Active MS Lesion Detection on Non-Contrast MRI, IEEE Access (2025). ##[13] S. Mura, P. Couvreur, Nanotheranostics for personalized medicine, Advanced drug delivery reviews 64(13) (2012) 1394-1416. ##[14] S. Rai, A. Nair, Z. Saleem, S.K. Ray, J.R. Kanwar, S. Mukherjee, Advancing nanotheranostics for neuro-immunological disorders: current status and future prospects, Neuroscience (2025). ##[15] A. Panghal, S. Flora, Nano-based approaches for the treatment of neuro-immunological disorders: A special emphasis on multiple sclerosis, Discover Nano 19(1) (2024) 171. ##[16] M.S. Muthu, D.T. Leong, L. Mei, S.-S. Feng, Nanotheranostics˗ application and further development of nanomedicine strategies for advanced theranostics, Theranostics 4(6) (2014) 660. ##[17] M.E. Lobatto, Z.A. Fayad, S. Silvera, E. Vucic, C. Calcagno, V. Mani, S.D. Dickson, K. Nicolay, M. Banciu, R.M. Schiffelers, Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis, Molecular pharmaceutics 7(6) (2010) 2020-2029. ##[18] M. Mahmoudi, M.A. Sahraian, M.A. Shokrgozar, S. Laurent, Superparamagnetic iron oxide nanoparticles: promises for diagnosis and treatment of multiple sclerosis, ACS chemical neuroscience 2(3) (2011) 118-140. ##[19] S.R. Ansari, J. Mahajan, A. Teleki, Iron oxide nanoparticles for treatment and diagnosis of chronic inflammatory diseases: A systematic review, Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 16(3) (2024) e1963. ##[20] C. Din, J. Xu, M. Vander Roest, H. Dobson, K.F. Olsen, A. Kim, H. Ju, A. Schwendeman, J.J. Moon, S.P. Schwendeman, Remote loading of an autoantigen in PLGA nanoparticles for the treatment of multiple sclerosis, Journal of Controlled Release (2025) 114298. ##[21] N.M. Phan, T.L. Nguyen, D.K. Min, J. Kim, Mesoporous polydopamine nanoparticle-based tolerogenic vaccine induces antigen-specific immune tolerance to prevent and treat autoimmune multiple sclerosis, Biomaterials 316 (2025) 122997. ##[22] L.A. Tziveleka, M. Cascione, P. Pellegrino, A. Bianco, S. Leporatti, V. De Matteis, Immunomodulatory natural polysaccharide‐based nanoparticles for the treatment of neurodegenerative diseases, ibrain 11(3) (2025) 277-296. ##[23] R.-G. Tauser, F.-G. Lupascu, B.-S. Profire, A.-T. Iacob, I.-M. Vasincu, M. Apotrosoaei, O.-M. Chirliu, D. Lupascu, L. Profire, Aptamer-Nanoconjugates as Potential Theranostics in Major Neuro-Oncological and Neurodegenerative Disorders, Pharmaceutics 17(9) (2025) 1106. ##[24] F. Kurul, H. Turkmen, A.E. Cetin, S.N. Topkaya, Nanomedicine: How nanomaterials are transforming drug delivery, bio-imaging, and diagnosis, Next Nanotechnology 7 (2025) 100129. ##[25] A. Sharma, N. Sharma, S. Singh, K. Dua, Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis, Journal of Drug Delivery Science and Technology 81 (2023) 104220. ##[26] S. Ranjbar, A. Bakhtiari, N. Khosravi, S.J. Ashkavandi, F. Azamian, M. Alijaniha, M. Karbalaee, Silver nanoparticles: biomedical applications and future perspectives, Journal of Composites and Compounds 6(20) (2024). ##[27] C. Saraiva, C. Praça, R. Ferreira, T. Santos, L. Ferreira, L. Bernardino, Nanoparticle-mediated brain drug delivery: Overcoming blood–brain barrier to treat neurodegenerative diseases, Journal of controlled release 235 (2016) 34-47. ##[28] J.W. Bulte, D.L. Kraitchman, Iron oxide MR contrast agents for molecular and cellular imaging, NMR in Biomedicine: An International Journal Devoted to the Development and Application of Magnetic Resonance In Vivo 17(7) (2004) 484-499. ##[29] F. Fathi, M. SEYEDSADJADI, C.M. GHAFFARI, Systematic review: Superparamagnetic Iron Oxide nanoparticles as contrast agents in diagnosis of multiple sclerosis, (2016). ##[30] V. Dousset, C. Delalande, L. Ballarino, B. Quesson, D. Seilhan, M. Coussemacq, E. Thiaudiére, B. Brochet, P. Canioni, J.M. Caillé, In vivo macrophage activity imaging in the central nervous system detected by magnetic resonance, Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine 41(2) (1999) 329-333. ##[31] M. Gkagkanasiou, A. Ploussi, M. Gazouli, E.P. Efstathopoulos, USPIO‐enhanced MRI neuroimaging: A review, Journal of Neuroimaging 26(2) (2016) 161-168. ##[32] M.M. Vellinga, R.D. Oude Engberink, A. Seewann, P.J. Pouwels, M.P. Wattjes, S.M. van der Pol, C. Pering, C.H. Polman, H.E. de Vries, J.J. Geurts, Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement, Brain 131(3) (2008) 800-807. ##[33] M. Rausch, P. Hiestand, D. Baumann, C. Cannet, M. Rudin, MRI‐based monitoring of inflammation and tissue damage in acute and chronic relapsing EAE, Magnetic Resonance in Medicine: An Official Journal of the International Society for Magnetic Resonance in Medicine 50(2) (2003) 309-314. ##[34] V. Dousset, L. Ballarino, C. Delalande, M. Coussemacq, P. Canioni, K.G. Petry, J.-M. Caillé, Comparison of ultrasmall particles of iron oxide (USPIO)-enhanced T2-weighted, conventional T2-weighted, and gadolinium-enhanced T1-weighted MR images in rats with experimental autoimmune encephalomyelitis, American journal of neuroradiology 20(2) (1999) 223-227. ##[35] J. Fatima, Y.H. Siddique, Application of nanocomposites and nanoparticles in treating neurodegenerative disorders, CNS and Neurological Disorders-Drug Targets-CNS and Neurological Disorders) 23(10) (2024) 1217-1233. ##[36] H. Li, X. Cong, H. Tan, J. Wang, H. Liu, X. Gao, K. Mao, G. Zhu, X. Meng, Y. Xin, Cationic lipid-modified PEG-PLGA nanoparticles facilitate effective dendritic cell reprogramming to alleviate T cell-mediated autoimmunity in EAE, Biomaterials (2025) 123784. ##[37] D.-E. Lee, H. Koo, I.-C. Sun, J.H. Ryu, K. Kim, I.C. Kwon, Multifunctional nanoparticles for multimodal imaging and theragnosis, Chemical Society Reviews 41(7) (2012) 2656-2672. ##[38] S.M. Dadfar, K. Roemhild, N.I. Drude, S. von Stillfried, R. Knüchel, F. Kiessling, T. Lammers, Iron oxide nanoparticles: Diagnostic, therapeutic and theranostic applications, Advanced drug delivery reviews 138 (2019) 302-325. ##[39] E.A. Neuwelt, B.E. Hamilton, C.G. Varallyay, W.R. Rooney, R.D. Edelman, P.M. Jacobs, S.G. Watnick, Ultrasmall superparamagnetic iron oxides (USPIOs): a future alternative magnetic resonance (MR) contrast agent for patients at risk for nephrogenic systemic fibrosis (NSF)?, Kidney international 75(5) (2009) 465-474. ##[40] D.M. Teleanu, C. Chircov, A.M. Grumezescu, R.I. Teleanu, Neurotoxicity of nanomaterials: An up-to-date overview, Nanomaterials 9(1) (2019) 96. ##[41] D.R. Getts, L.D. Shea, S.D. Miller, N.J. King, Harnessing nanoparticles for immune modulation, Trends in immunology 36(7) (2015) 419-427. ##[42] P.A. Jarzyna, L.H. Deddens, B.H. Kann, S. Ramachandran, C. Calcagno, W. Chen, A. Gianella, R.M. Dijkhuizen, A.W. Griffioen, Z.A. Fayad, Tumor angiogenesis phenotyping by nanoparticle-facilitated magnetic resonance and near-infrared fluorescence molecular imaging, Neoplasia 14(10) (2012) 964-973. ##[43] H. Tiwari, S. Singh, R. Kumar, A. Mandal, A. Pathak, N.K. Verma, L. Kumar, V. Gautam, Novel advancements in nanomaterials-based contrast agents across multimodal imaging and theranostic applications, Nanoscale Advances 7(21) (2025) 6753-6773. ##[44] T. Knopp, N. Gdaniec, M. Möddel, Magnetic particle imaging: from proof of principle to preclinical applications, Physics in Medicine and Biology 62(14) (2017) R124-R178. ##[45] M.L. Etheridge, S.A. Campbell, A.G. Erdman, C.L. Haynes, S.M. Wolf, J. McCullough, The big picture on nanomedicine: the state of investigational and approved nanomedicine products, Nanomedicine: nanotechnology, biology and medicine 9(1) (2013) 1-14. ##[46] H.K. Makadia, S.J. Siegel, Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier, Polymers 3(3) (2011) 1377-1397. ##[47] S. Hua, M.B. De Matos, J.M. Metselaar, G. Storm, Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization, Frontiers in pharmacology 9 (2018) 790. ##[48] B. Fadeel, L. Farcal, B. Hardy, S. Vázquez-Campos, D. Hristozov, A. Marcomini, I. Lynch, E. Valsami-Jones, H. Alenius, K. Savolainen, Advanced tools for the safety assessment of nanomaterials, Nature nanotechnology 13(7) (2018) 537-543. ##[49] R.J. Gillies, P.E. Kinahan, H. Hricak, Radiomics: images are more than pictures, they are data, Radiology 278(2) (2016) 563-577. ##[50] A. Hosny, C. Parmar, J. Quackenbush, L.H. Schwartz, H.J. Aerts, Artificial intelligence in radiology, Nature Reviews Cancer 18(8) (2018) 500-510. ##[51] J.A. Doudna, The promise and challenge of therapeutic genome editing, Nature 578(7794) (2020) 229-236. ##[52] T.C. Roberts, R. Langer, M.J. Wood, Advances in oligonucleotide drug delivery, Nature reviews Drug discovery 19(10) (2020) 673-694. ##[53] P. Lambin, R.T. Leijenaar, T.M. Deist, J. Peerlings, E.E. De Jong, J. Van Timmeren, S. Sanduleanu, R.T. Larue, A.J. Even, A. Jochems, Radiomics: the bridge between medical imaging and personalized medicine, Nature reviews Clinical oncology 14(12) (2017) 749-762.